Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alendronate sodium + beta-tricalcium phosphate
- Development stage
- Unknown
- Lead developer
- Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems, Device-based Delivery → Drug Delivery Systems
- Administration
- Local
01
Overview
Alendronate sodium + beta-tricalcium phosphate is an experimental combination therapy being evaluated for the treatment of periodontal intra-osseous defects. Alendronate sodium is an aminobisphosphonate that primarily inhibits osteoclast-mediated bone resorption by targeting farnesyl pyrophosphate synthase. In this specific application, 400µg of alendronate sodium is locally delivered using beta-tricalcium phosphate (β-TCP) as a bioactive, osteoconductive bone substitute. The combination aims to enhance bone formation and clinical attachment levels in dental patients with periodontal defects. The Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre conducted a Phase 4 clinical trial in Hyderabad, India, to assess its efficacy compared to β-TCP alone.
- Other names
- alendronate with beta-TCPalendronate sodium in beta-tricalcium phosphate400µg alendronate delivered in beta-TCP
02
Targets
FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on alendronate sodium + beta-tricalcium phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alendronate sodium + beta-tricalcium phosphate.